Environmental Assessment Of The Final Effluent Limitations Guidelines And Standards For The Pharmaceutical Manufacturing Industry, Final Report.
This report presents an assessment of the water quality-related and air quality-related benefits from the Clean Water Act (CWA) final effluent limitations guidelines for the Pharmaceutical Manufacturing Industry, as well as the benefits expected to accrue from the corresponding Maximum Achievable Control Technology (MACT) standards under the Clean Air Act (CAA). This assessment considers the benefits expected to result from implementation of these rules due to reductions in effluent loadings and air emissions. A variety of human health, environmental, and publicly-owned treatment works (POTW) benefits might result from these reductions. The assessment includes a qualitative description of each benefit category and provides quantitative estimates of economic (monetized) benefits for those benefit categories for which there are sufficient data to develop such estimates.
|Office of Water|
|Office of Science and Technology|
|Standards and Applied Science Division|
|Harrigan, Patricia; Healy, Richard|
|Background Cost-Related Document|